Monica Gadelha, DR, PhD, at the University of Rio De Janeiro discusses the PATHFNDR-1 trial and acromegaly.
Transcription:
The patients that finish the core phase can enter in the extension phase. The vast, vast majority, I think that’s more than 90% of the patients opted to go to the extension, so they will stay on paltusotine. Besides that, there is ongoing other phase 3 study. The pragmatics are doing another phase 3 that includes a different study.
The period of inclusion is stopped, but we included patients that are naive to drugs, patients that were without the drug for some period, or patients that had to do a washout of the drug. So, it’s a different patient population. It will be very nice to see the results of the PATHFNDR-2.
At the moment, I have many patients in our center, some in the extension of the PATHFNDR-1, some in the extension of the phase 2, and some in the core phase of the PATHFNDR-2. In Brazil, until the medication is available for the patient, the pharma must provide the medication.
To learn more about acromegaly and other endocrine disorders, click here: https://checkrare.com/diseases/endocrine-disorders/
